CTOs on the Move

Good Therapeutics

www.goodtherapeutics.com

 
Good Therapeutics is an early-stage biotechnology company based in Seattle, Washington. We are developing "context-dependent" protein drugs that sense biomarkers and respond with a therapeutic activity. Our goal is to make safer, more effective drugs that act only when and where they are needed, limiting systemic toxicity without reducing therapeutic efficacy.
  • Number of Employees: 0-25
  • Annual Revenue: $0-1 Million

Executives

Name Title Contact Details

Funding

Good Therapeutics raised $11M on 05/21/2020

Similar Companies

SkylineDx

SkylineDx is a pioneer in the field of molecular diagnostics through developing and commercializing innovative, signature-based diagnostics with a high clinical value that help to provide physicians and patients with the best individual care possible. At SkylineDx we transform life sciences into the daily practice of clinical diagnostics. We enable patients to benefit sooner and safer from new insights in the molecular basis of disease. We can truly make a difference by making our love of life tangible as state-of-the-art diagnostic products with a high clinical value. Our products are designed to support clinicians in making the right choices for their patients. This provides a unique and very real difference. Obvious perhaps, but never taken for granted here at SkylineDx.

Atsena Therapeutics

Atsena Therapeutics is a clinical-stage gene therapy company focused on bringing the life-changing power of genetic medicine to reverse or prevent blindness.

Stemline Therapeutics

Stemline Therapeutics is a clinical stage biopharmaceutical company developing oncology compounds that target cancer stem cells.

CymaBay

CymaBay Therapeutics is a clinical-stage biopharmaceutical company located in the San Francisco Bay Area focused on developing therapies to treat metabolic diseases with high unmet medical need or serious rare and orphan diseases. We are committed to developing breakthrough medicines that improve the lives of patients and their families. CymaBay was seeded with the assets from an earlier metabolic disease company in which more than $120M was invested to produce a robust pipeline.

Solugen

Solugen is a venture-backed biotech startup that replaces petroleum based products with plant-derived substitutes.